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Abstract: Cow’s milk protein allergy (CMPA) is associated with dysbiosis of the infant gut micro-
biome, with allergic and immune development implications. Studies show benefits of combining
synbiotics with hypoallergenic formulae, although evidence has never been systematically examined.
This review identified seven publications of four randomised controlled trials comparing an amino
acid formula (AAF) with an AAF containing synbiotics (AAF-Syn) in infants with CMPA (mean age
8.6 months; 68% male, mean intervention 27.3 weeks, n = 410). AAF and AAF-Syn were equally effec-
tive in managing allergic symptoms and promoting normal growth. Compared to AAF, significantly
fewer infants fed AAF-Syn had infections (OR 0.35 (95% CI 0.19–0.67), p = 0.001). Overall medication
use, including antibacterials and antifectives, was lower among infants fed AAF-Syn. Significantly
fewer infants had hospital admissions with AAF-Syn compared to AAF (8.8% vs. 20.2%, p = 0.036;
56% reduction), leading to potential cost savings per infant of £164.05–£338.77. AAF-Syn was as-
sociated with increased bifidobacteria (difference in means 31.75, 95% CI 26.04–37.45, p < 0.0001);
reduced Eubacterium rectale and Clostridium coccoides (difference in means −19.06, 95% CI −23.15 to
−14.97, p < 0.0001); and reduced microbial diversity (p < 0.05), similar to that described in healthy
breastfed infants, and may be associated with the improved clinical outcomes described. This review
provides evidence that suggests combining synbiotics with AAF produces clinical benefits with
potential economic implications.
Keywords: paediatrics; allergy; cow’s milk protein allergy; synbiotics; gut microbiome; amino acid
formula; clinical outcomes
1. Introduction
Cow’s milk protein allergy (CMPA) is one of the most common food allergies in
children, typically diagnosed in the first year of life with an estimated prevalence of around
2–5% of infants in Europe [1–4]. Analysis of National Health Service (NHS) records showed
that, overall, allergic conditions account for 12.5 million GP consultations and 183,000
admitted bed days annually in the UK, costing over £1bn [5], with additional direct and
indirect household costs [6]. Moreover, the impact of CMPA on quality of life is substantial,
with anxiety, frustration and social limitation being prominent issues for families [7,8].
Around 44% of infants with CMPA show a specific IgE response, with the remainder of
cases being considered non-IgE mediated [4]. However, the presence or absence of specific
IgE alone should not determine treatment, as approaches to management are based on
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eliminating exposures to cow’s milk protein (CMP) and may vary according to age of the
infant, severity of the condition and current feeding methods [2,3,9].
Breastfeeding remains the best option in CMPA and generally avoids exposure to CMP.
Where breastfeeding is not possible, partially or fully formula-fed infants with CMPA may
require management with hypoallergenic formulae (HAF) [2,3,9]. Most guidelines recom-
mend the use of extensively hydrolysed formula (eHF) first-line in the majority of infants
with CMPA; in severe or complex CMPA, or where symptoms do not resolve with eHF,
amino acid formula (AAF) is recommended [2,3,9,10]. Although HAF are recommended
in clinical guidelines, impacts on gut microbiota are important considerations, as they are
widely recognised to play an important role in allergy and immune development [11–13].
In healthy breastfed infants, faecal microbiota is characterised by a relative preponder-
ance of Lactobacillus and Bifidobacterium, with fewer other organisms such as Bacteroides,
Clostridium, and Enterobacteriaceae [14–17]. CMPA is associated with gut dysbiosis [14]
and the development of other allergic conditions in later childhood [12,13]. Whilst difficult
to establish causality, it is hypothesised that early intestinal dysbiosis may disrupt regula-
tory mechanisms of the immune response, triggering pro-allergic processes and increased
risk of allergy [18]. Therefore, modification of the gut microbiome warrants investigation
as a potential strategy in CMPA management. One approach to this is the use of prebiotic
and probiotic-supplemented infant formulae.
A probiotic consists of live microorganisms intended to improve health [11] while
a prebiotic is a microbial substrate that allows specific changes in the composition and
activity of the gastrointestinal microbiota to confer a health benefit [19,20]. Probiotics
(given within formulae or as an adjuvant treatment to formula) have been associated with
earlier resolution of CMPA [21] and the use of formula containing prebiotics has been
shown to enhance levels of Bifidobacterium species in formula-fed infants [22,23], being
more similar to those of healthy breast-fed infants [24]. When used together, probiotics
and prebiotics are termed complementary synbiotics [25]. The impact of synbiotics when
taken as an adjuvant to both breast-feeding and formula feeding has also been evaluated
in infants with CMPA, showing increases in weight and head circumference [26], enhanced
gut Lactobacillus and Bifidobacterium [27] and reductions in atopic eczema [27,28], with lower
risk of respiratory infections and antibiotic usage [28]. There is also emerging evidence from
individual randomised controlled trials (RCTs) investigating the effect of hypoallergenic
formula containing synbiotics, but to date there has not been a comprehensive review
summarising these findings. Therefore, this systematic review was undertaken to examine
whether HAF (eHF and AAF) containing synbiotics could have a beneficial effect on clinical
outcomes, including clinical symptoms and allergenicity, rates of infections, hospitalisation,
medication usage, gut microbiota colonisation, stool characteristics and growth in infants
with CMPA.
2. Materials and Methods
2.1. Identification and Selection of Studies for the Systematic Literature Review
An online search strategy, devised in accordance with PRISMA guidelines, was carried
out using MEDLINE, EMBASE and Cochrane Library up to November 2020. Specific
search strategies were developed for each data source using an initial broad approach
based on the following structure: Infant Feed [SUBJ] OR Milk [TW] OR Formula [TW]
AND Probiotic [SUBJ/TW] OR Prebiotic [SUBJ/TW] OR Synbiotic [SUBJ/TW]. Hand
searching of pre-determined international allergy conference proceedings (EAACI; EAACI
PAAM; FAAM-EUROBAT) was undertaken and secondary searches were carried out by
hand-searching reference lists of all full text publications obtained. Previously published
systematic reviews were particularly sourced for this purpose.
After elimination of duplicates, identified abstracts were screened against defined
inclusion and exclusion criteria. Only publications reporting on RCTs qualified for review.
Subjects eligible for inclusion were infants and children aged <3 years with IgE or non IgE
mediated CMPA. Studies of older children, children without CMPA, adults and animals
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were excluded. Suitable interventions were any AAF with synbiotics (AAF-Syn) or eHF
with synbiotics (eHF-Syn). Studies of infant formulae containing cow’s milk protein, and
eHF or AAF without synbiotics (including those with only a prebiotic or a probiotic) were
excluded. No restrictions were placed on sample size, duration of intervention, or type of
comparator. Full papers, abstracts and conference proceedings were eligible for inclusion.
Only English language publications were eligible.
2.2. Quality Assessment
Quality assessment was conducted by one researcher and verified by a second as-
sessor. Any discrepancies were resolved by discussion. Publications which passed the
initial screen were obtained in full to ascertain a final inclusion decision. The quality of all
included publications were assessed using the Cochrane Risk of Bias tool for randomised
trials (ROB-2) [29]. This tool evaluates study quality in five domains; judgement can be
‘Low’, or ‘High’ risk of bias, or can express ‘Some concerns’, meaning a publication has
concerns in at least one domain but is not at high risk of bias for any domain. Additional
information was obtained through personal communication with the author for the in-
cluded abstracts [30,31]. It was intended that publications at high risk of bias would not be
included in the review.
2.3. Data Extraction and Outcome Measures
A pre-determined data collection table was designed to capture study characteristics
and outcome data. Outcome measures sought included clinical symptoms (e.g., atopic
dermatitis, general allergy symptoms), infections and healthcare usage (e.g., medication
and hospitalisation), gut microbiota profiles from faecal samples, growth and stool charac-
teristics. Direct communication with publication authors was undertaken where needed
to obtain additional data or clarification. Following data extraction from eligible studies,
meta-analysis was conducted for comparable data where possible. Outcomes that could
not be meta-analysed are described in the text.
2.4. Statistical Methods
Throughout this review, data were presented as means from the RCTs (n = 4) not from
the publications (n = 7) to avoid any double counting. To account for differences in sample
size between studies, data (including age, intervention duration and intake) were presented
as weighted averages and, in some instances, as cumulative averages. Cumulative averages
were calculated by pooling data across studies and weighting results according to study
sample size, omitting data from one publication [32] where the same outcome was reported
in the study follow-up publication [33] to avoid double counting.
Meta-analysis was conducted using Comprehensive Meta Analysis Version 3 (Biostat©,
New Jersey, USA), using a fixed effects model, with random effects for sensitivity analysis
where the I2 approached 50 or over. Data were presented as either difference in means and
95% confidence intervals (95% CI) or odds ratio and 95% CI. Meta-analysis of microbiota
data was undertaken using data extracted from the last timepoint of each publication.
In the absence of quantifiable data for the whole cohort, subset data (for infants who
received the intervention for the full 26 week follow-up) was used for one publication [33].
Sensitivity analysis was conducted using the first post-intervention timepoint for each
publication. Where mean values were not available, the median was used, in line with Hozo
et al. [34]. If not explicitly stated, standard deviation was estimated by back-calculation
from published confidence intervals. Where this was not available, an estimate was made
from the median and range values, as described elsewhere [34]. Overall significance was
assumed at p < 0.05. Forest plots were used to present meta-analysis data. Further details
of the statistical methods associated with meta-analysis are described elsewhere [35].
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2.5. Simple Cost Analysis
A simple cost-analysis was conducted from the data available on hospital admis-
sions [31], based on the average cost of a paediatric hospital admission for major infec-
tion [36] and accounting for the cost of HAF containing synbiotics and HAF (without
synbiotics) [37], to estimate an annual healthcare budget impact per infant.
3. Results
3.1. Overall Search Findings (n = 7)
A total of 3684 publications were identified by the search strategy (Figure 1). After
removal of duplicates, and evaluation of the title and/or abstract, 116 publications were
potentially relevant and obtained in full. Following full text review, seven publications (5
full papers, 2 abstracts) were deemed eligible for inclusion, reporting data from 4 RCTs
(n = 410; mean age 8.6 months; 68% male) [30–33,38–40]. The other 109 publications were
excluded from the systematic review due to not including a CMPA population (n = 75, of
which four were full papers including eHF-Syn in atopic infants); infants not being formula
fed (n = 1); not including synbiotics (n = 17); being a prevention study (n = 10); being a
review article (n = 2); being a single-arm study (n = 3 abstracts including eHF-Syn in infants
with CMPA); and being an abstract superseded by a full publication (n = 1).




Figure 1. PRISMA flow chart. 
  
Figure 1. PRISMA flow chart.
3.2. Description of Publications Included in the Systematic Review (n = 7)
The seven publications [30–33,38–40] included in the systematic review are shown
in Tables 1 and 2. These report results from 4 RCTs on the use of AAF with synbiotics
(AAF-Syn) in infants with CMPA (of which one also reported on a one-arm double blind
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placebo-controlled crossover food challenge [38]). Two of the full papers [33,40] report
additional outcomes from the same primary RCT (ASSIGN study) [32] and both abstracts
report different outcomes from the same primary RCT (PRESTO study [30,31]). In all seven
publications, infants with confirmed CMPA (including infants with IgE mediated and
non IgE mediated CMPA) were given a standard AAF supplemented with the probiotic
Bifidobacterium breve M16-V and prebiotics (including chicory-derived neutral oligo-fructose
and long chain inulin). No eligible publications of alternative HAF with synbiotics were
identified by this review. Although the systematic search found four studies [41–44] of
eHF-Syn, they were conducted in atopic infants but not with a diagnosis of CMPA, and
were therefore excluded. Intervention periods across the 7 included publications ranged
from 7 days to 12 months (weighted mean 4 RCT [31,32,38,39] 27.3 weeks), with follow-up
for the included outcomes ranging from 7 days to 12 months. The total number of patients
studied in a single RCT ranged from 60 to 169 (Table 1). The average daily intake of the
AAF with synbiotics reported ranged from 349 mL to 652 mL (calculated intakes based on
standard dilution of 237 to 443 kcal, 6.6 to 12.4 g protein; weighted mean without double
counting publications of the same RCT [31,32,38]: 389 mL, 265 kcal, 7.4 g protein).
When assessing the quality of the studies, overall the majority of publications were at
low risk of bias (Figure 2).
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Table 1. Summary of included publications.















Infants with IgE mediated CMPA aged
0–36 months
One arm DBPCCFC and 7 day feeding
period
61% 17.3, range3.3–46.9 Not reported 30 30 7 days 7 days
Full-term healthy infants aged 3–16 months,
RCT ¶ 67% 10.6, range 3–16
AAF-Syn: 349 ± 127 §;
AAF: 331 ± 124 § 59 56 16 weeks




Infants with IgE or non-IgE mediated









Infants with non-IgE mediated CMPA
aged 0–13 months, RCT




AAF-Syn 652 ± 176;
AAF 639 ± 212
35 36 8 weeks 4 & 8 weeks
Fox (2019) [33] †
ASSIGN study, full
paper
Infants with non-IgE mediated CMPA
aged 0–13 months
26-week follow-up of Candy (2018)
73% 6, range1.2–12.8
Week 8
AAF-Syn 652 ± 176;
AAF 639 ± 212
35 36 8 weeks 8, 12 &26 weeks
Wopereis (2019) [40] †
ASSIGN study, full
paper
Infants with non-IgE mediated CMPA
aged 0–13 months
Gene-sequencing analysis from Candy
(2018) and Fox (2019)
73% 6, range1.2–12.8
Week 8
AAF-Syn 652 ± 176;
AAF 639 ± 212




Infants with confirmed IgE mediated
CMPA aged 0–13 months, RCT 72% 9.36, SD 2.53
At 12 months:
AAF-Syn: 547 ± 302;
AAF: 530 ± 308




Infants with confirmed IgE mediated
CMPA aged 0–13 months, RCT
CMPA: cow’s milk protein allergy; RCT: randomised controlled trial; DBPCCFC: double blind placebo-controlled crossover food challenge; AAF-Syn: amino acid formula with synbiotics (Neocate Syneo®,
Nutricia); AAF (control): amino acid formula (Neocate LCP®, Nutricia); † original RCT (Candy 2018 [32]) was for 8 weeks, Fox (2019) [33] and Wopereis (2019) [40] were published after original RCT; ‡ Chatchatee
(2019) [31] and Wopereis (2020) [30] report different outcomes from same study; § Converted from reported oz/d (11.8 ± 4.3 oz/d AAF-Syn; 11.2 ± 4.2 oz/d AAF); ¶ Included in table for completeness, but
outside scope of review as subjects were not required to have CMPA.
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Infants with confirmed IgE
mediated CMPA aged 0–13 months
PO
X
CMPA: cow’s milk protein allergy; GI: gastrointestinal. PO: primary outcome (PO for Chatchatee (2019) [31] was cow’s milk protein tolerance, not included in this review); Xnumerical improvement with
amino acid formula containing synbiotics (AAF-Syn) vs. amino acid formula (AAF); XXsignificant improvement AAF-Syn vs. AAF; = no difference; empty boxes without symbols indicate that outcome was
not reported. † Atopic dermatitis/general allergy symptoms/response to double blind placebo-controlled food challenge ‡ Respiratory § XAntifungals/emollients/functional gastrointestinal/unspecified
concomitant ¶ Subset who received intervention for 26 weeks # Included in table for completeness, but outside scope of review as subjects were not required to have CMPA.
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3.3. Outcomes from Studies Comparing AAF with Synbiotics with AAF Alone
3.3.1. Clinical Symptoms & Allergenicity
Four publications (3 RCT; n = 241) reported clinical symptoms and allergenicity in
infants with IgE or non IgE mediated CMPA who received AAF-Syn or AAF for periods
ranging from 7 days to 16 weeks [32,33,38,39], although quantitative data was not given
in all cases (Supplementary Table S1). Three publications reported on SCORing Atopic
Dermatitis (SCORAD) [45] and on clinical rating scales such as gastrointestinal, skin,
respiratory and general symptoms [32,33,39] and one publication reported data from a
double-blind placebo-controlled crossover food challenge (DBPCCFC) [38]. Data from all
publications showed that both AAF-Syn and AAF were hypoallergenic. Improvement in
clinical symptoms were reported over time in both groups, with no significant differences
between groups in all three publications reporting symptoms, and both formulae led to a
negative response in a DBPCCFC [38].
3.3.2. Infections and Hospital Admissions
Four publications (3 RCT; n = 350) reported data on infections from adverse event data,
in infants with IgE and non IgE mediated CMPA who received AAF-Syn or AAF alone,
over periods from 8 weeks to 12 months (Table 3) [31–33,39]. All four publications reported
fewer infants receiving AAF-Syn had infections, compared to those receiving AAF alone,
which was statistically significant in two publications [31,39]. One of these publications
reported additional specific data on ear infections, finding significantly fewer infants who
received AAF-Syn had at least one ear infection, compared to those who received AAF
alone (0% vs. 20%; p = 0.011) [33].
Pooled analysis of infections data from three of the four publications (omitting data
from one publication [32] to avoid double-counting) showed a lower cumulative average
percentage of infants who had infections with AAF-Syn vs. AAF alone (13.6% vs. 27.8%,
respectively) (Table 3), equating to more than 50% reduction overall.




n/N % n/N %
Burks (2015) [39] 1/54 1.9% 10/56 17.9%
Candy (2018) [32] † (ASSIGN study) 10/35 28.6% 12/36 33.3%
Fox (2019) [33] (ASSIGN study) 15/35 42.9% 22/35 62.9%
Chatchatee (2019) [31] (PRESTO study) 7/80 ‡ 8.8% 18/89 ‡ 20.2%





Percentage reduction 51.0% (58.6% §)
AAF-Syn: amino acid formula with synbiotics. AAF: amino acid formula. † Pooled result omits data from Candy (2018) [32] as data from
Fox (2019) [33] (26 week follow up) is inclusive of data from Candy (2018) [32]. ‡ Calculated from reported percentages of sample size.
§ Result weighted by study sample size.
Meta-analysis (omitting data from one publication [32] to avoid double-counting)
showed that the proportion of infants who had infections was significantly lower with
AAF-Syn than with AAF alone (OR 0.35 (95% CI 0.19 to 0.67), p = 0.001, I2 = 0, fixed effects,
3 publications, Figure 3) [31,33,39].
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Figure 3. Meta-analysis showing significantly lower rates of infection with AAF-Syn vs. AAF. Abbreviations: AAF-Syn:
amino acid formula with synbiotics. AAF: amino acid formula. CI: confidence intervals.
Hospital admissions arising from infections were reported in one publication [31],
which showed significantly few r infa ts had admissions with AAF-Syn compared to AAF
alone (8.8% vs. 20.2%; p = 0.036), equating to a 56% reduction.
Simple Cost Analysis Based on Hospital Admission Data
The ap roximated average cost of a paediatric hospital admission for a serious infec-
tion in England ranges from £1756 to £7 92 [36], with a calculated mean cost per patient
per admission of £3811. Based on this, looking at hospital admission rates alone, assuming
each patient within this review who was recorded as having hospital admissions had only
one admission, and accounting for the cost of the A F-Syn and A F powders [37], there
is an annual potential mean cost saving of between £164.05 per infant (based on reported
intakes and duration from the publication which reported hospital admissions [31]) and
£338.77 per infant (based on weighted mean intake and duration data from all included
RCTs which reported intakes [31,32,38]).
3.3.3. Medication Use
Three publications (2 RCT; n = 181) reported data on medication usage [32,33,39]
in infants with IgE and non IgE mediated CMPA who received either AAF-Syn or AAF
for 8 to 16 weeks (Table 4). Medications reported across the publications included over-
all concomitant medication use (not specified); antibacterials and anti-infectives (which
includes antibiotics); dermatologicals; antifungals; emollients; and functional GI medica-
tions [32,33,39].
All three publications which had available data on antibacterial, anti-infective or an-
tibiotic usage found fewer infants in the AAF-Syn group used these medications, compared
to the AAF group (range 9–17% with AAF-Syn vs. 31–34% with AAF). This was shown
to be statistically significant in two publications (p < 0.05) [32,39]; whilst a p-value was
not available in one publication [33] as data were calculated from details of the subgroups
who received systemic antibiotics during the study period. Pooled analysis showed the
weighted average percentage of infants using antibacterials, anti-infectives or antibiotics
was 15% with AAF-Syn vs. 33% with AAF, equating to a 55% reduction. When omitting one
publication [32] to avoid double counting, results were similar (17% vs. 33%, respectively;
48% reduction).
Similarly, all three publications found lower usage of other medications with AAF-Syn
than with AAF alone, with statistically significant differences reported in two of the three
publications (p < 0.05) [33,39]. Of these, one publication reported extensively on ‘other’
medication usage, finding fewer infants using ‘other’ medications with AAF-Syn com-
pared to AAF alone across all categories, most significantly for dermatologicals (p = 0.019),
emollients and protectives (p = 0.023) and antifungals (p = 0.054) [33]. One publication
reported significantly fewer infants received functional GI medication (p = 0.029) [39] with
AAF-Syn. Pooled analysis showed that AAF-Syn was associated with a lower overall
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percentage of infants using emollients, protectives and dermatological medications (−69%);
and concomitant medications (−19%; −14% when omitting one publication [32] to avoid
double counting).
Table 4. Individual publication results of the percentage of infants receiving medications with AAF-Syn vs. AAF.
Lead Author (Date) Outcome Measures Comparison of Findings in AAF-Syn vs. AAF Groups
Burks (2015) [39]
Systemic antibacterial and functional GI
medication use included as exploratory
outcome
Results AAF-Syn vs. AAF, 16-week event rates:
Systemic antibacterial use: 17% vs. 34%, p = 0.049
- Amoxicillin use: 9% vs. 32%, p = 0.004
Functional GI medication use: 4% vs. 18%, p = 0.029
Candy (2018) [32]
ASSIGN study
Systemic anti-infective & concomitant
medication use included as exploratory
outcome
Results AAF-Syn vs. AAF, 8-week event rates:
Overall concomitant medication use: 60% vs. 78% †, p = 0.117
- Systemic anti-infectives use: 9% vs. 33% †, p = 0.018
Fox (2019) [33] ‡
ASSIGN study
Concomitant medication use included as
exploratory outcome
Results AAF-Syn vs. AAF, 26-week event rates:
Overall concomitant medication use: 71% vs. 83%, p = 0.39
- Dermatological use: 17% vs. 46%, p = 0.019
- Antifungal use: 0% vs. 14%, p = 0.054
- Emollients & protectives use: 6% vs. 29%, p = 0.023
- Antibiotics use §: 17% vs. 31%, no p-value
AAF-Syn: amino acid formula with synbiotics. AAF: amino acid formula. GI: Gastrointestinal. † Percentage calculated due to error in study
table. ‡ Data from Fox (2019) [33] is inclusive of data from Candy (2018) [32], as a 26 week follow up. § Calculated from reported size of
sub-groups that did not take systemic antibiotics as a proportion of the total size of each group (Figure 1) [33].
3.3.4. Change in Gut Microbiota Profile
In total, five publications (3 RCT; n = 350) reported on gut microbiota from faecal
samples in infants with IgE and non IgE mediated CMPA, following feeding with AAF-Syn
or AAF for periods ranging from 8 weeks to 12 months [30,32,33,39,40] (Table 5). The
different ways in which this was measured in each publication is summarised below.
Of these five publications that reported on gut microbiota from faecal samples, three
provided data on faecal proportions of bacteria (Bifidobacterium species and Clostridium
histolyticum (CH), Eubacterium rectale (ER) and Clostridium coccoides (CC) groups) as a per-
centage of total bacteria, from baseline to timepoints ranging from 8 to 26 weeks [32,33,39].
Of these, two publications reported data from a subgroup analysis of infants who a) had
not received antibiotic treatment and b) had remained on the originally allocated formula
until week 26 (completers) [32,33].
One publication reported data on faecal bacterial diversity (phylogenetic diversity (PD)
and Shannon index (SI)) assessed by 16S rRNA-gene sequencing [40]. One publication did
not report detailed data, but described differences in relative abundances of Bifidobacterium
species, Lactobacillus species, Blautia, Tyzzerella and Romboutsia, and differences in faecal
bacterial diversity, at 6 and 12 months [30].
Two publications reported data on markers of bacterial metabolic activity including
pH, short chain fatty acids and lactic acids [39,40]. Two publications also provided compar-
ative data from a reference group of 51 age-matched healthy breastfed infants on faecal
proportions of bacterial species [32], faecal bacterial diversity and markers of bacterial
metabolic activity [40], at 8 weeks.
Data from all three publications [32,33,39] reporting data on faecal proportions of
bacteria found that, compared to AAF alone, AAF-Syn resulted in significantly greater
percentages of Bifidobacterium species and significantly lower percentages of Eubacterium
rectale and Clostridium coccoides species. The fourth publication [30] described similar trends,
although statistical significance was not reported. By pooling the available quantifiable data
from all post-intervention timepoints of the three publications, a weighted average could be
calculated, which showed that the average percentage of Bifidobacterium species was higher
in infants who received AAF-Syn (44.0%) than those who received AAF alone (12.2%),
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whilst Eubacterium rectale and Clostridium coccoides was lower (11.7% vs. 29.5%, respectively).
All three publications reported no significant differences between groups at baseline, yet
only two provided quantifiable data, which showed that the absolute increase over time in
Bifidobacterium species was greater with AAF-Syn than AAF alone when taken for 16 weeks
(+36.9% vs. −3.7%) [39] and 26 weeks (+22.2% vs. −2.6%) [33]. In addition, they showed a
decrease in Eubacterium rectale and Clostridium coccoides (AAF-Syn −10.0% vs. AAF alone
+15.4% over 16 weeks [39]; AAF-Syn −10.5% vs. AAF alone +20.5% over 26 weeks [33]).
The higher proportions of Bifidobacterium species and lower proportions of Eubacterium
rectale and Clostridium coccoides after feeding with AAF-Syn were found to be more similar
to the bacterial profile of healthy breastfed infants (Bifidobacterium species 55%, Eubacterium
rectale and Clostridium coccoides 6.5%) by the publication which provided comparative data
on faecal bacterial proportions from a healthy breastfed reference group [32].
Meta-analysis using data from the last timepoint of each publication (8–26 weeks)
showed that AAF-Syn significantly increased percentages of Bifidobacterium species (differ-
ence in means 31.75, 95% CI 26.04–37.45, p < 0.0001, I2 = 49.34, fixed effects, 3 publications,
Figure 4) and significantly decreased percentages of Eubacterium rectale and Clostridium
coccoides (difference in means −19.06, 95% CI −23.15 to −14.97, p < 0.0001, I2 = 18.14, fixed
effects, 3 publications, Figure 5). When meta-analysis was undertaken using a random ef-
fects model for completeness, results were similar and remained significant (Bifidobacterium
species difference in means 32.15, 95% CI 23.78–40.51, p < 0.0001; Eubacterium rectale and
Clostridium coccoides difference in means −19.01, 95% CI −23.63 to −14.40, p < 0.0001).
Sensitivity analysis using the earliest post-intervention timepoints of each publication
(4–8 weeks) showed similar results (difference in means for Bifidobacterium species 28.02,
95% CI 22.01–34.03, p < 0.0001, fixed effects, I2 = 0, 3 publications; difference in means for
Eubacterium rectale and Clostridium coccoides −14.72, 95% CI −19.17 to −10.27, p < 0.0001,
fixed effects, I2 = 0, 3 publications). When excluding one publication [32] to avoid any
potential double counting of the same outcome which was also reported in the study’s
follow-up publication [33], the results were similar and remained statistically significant.
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Data from the two publications [32,33] that reported subgroup analysis indicated that
infants who had not received antibiotic treatment and who remained on their allocated
formula for 26 weeks had results consistent with the primary analysis.
Both publications which reported on bacterial diversity showed that this was lower
overall with AAF-Syn compared to AAF alone [30,40]. The one publication [40] which
reported specific data on bacterial diversity found that, while diversity in faecal microbiota
increased over time in both groups, this was less pronounced among infants who received
AAF-Syn than those who received AAF alone. At week 8, the bacterial diversity of infants
who received AAF-Syn (PD 4.89 ± 1.05; SI 3.75 ± 0.67) was closer to that of the healthy
breastfed reference group (PD 4.37 ± 1.14; SI 3.63 ± 0.80) than the infants who received
AAF alone (PD 5.17 ± 0.88; SI 4.01 ± 0.71).
The two publications [39,40] that reported data on markers of bacterial metabolic
activity showed that, compared to AAF alone, AAF-Syn was associated with significant
differences, notably lower faecal pH (5.82 ± 0.72 vs. 6.72 ± 0.47, p < 0.001) and propionic
acid (11.4% ± 7.3 vs. 22.6% ± 21.4, p = 0.006) and higher acetic acid (80.7% ± 10.7 vs.
68.6% ± 21.5, p = 0.004) when given for 16 weeks [39], although significant differences
were not observed at 8 weeks [40].
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Table 5. Individual publication results of changes in faecal microbiota profile among infants receiving AAF-Syn vs. AAF.
Lead Author




change in proportion of
faecal BSp, CH & ER/CC
Mean AAF-Syn vs. AAF. Baseline proportions similar in both groups
- BSp: 14.3% vs. 16.7%, p = 0.60 NS
- CH: 9.3% vs. 9.1%, p = 0.93 NS
- ER/CC: 23.8% vs. 20.1%, p = 0.30 NS
At 16 weeks significant differences observed:
- BSp: 51.2% vs. 13.0%, p < 0.001
- CH: 7.1% vs. 17.6%, p < 0.001
- ER/CC: 13.8% vs. 35.5%, p < 0.001
All differences between
groups at 16 weeks
statistically significant
“The indigenous gut microbiota of [CMPA] infants receiving
an AAF can be influenced by synbiotics. As expected,
synbiotics in the test formula increased Bifidobacterium, a
genus typically predominant in the GI tract of breastfed
infants”
“ . . . It can therefore be hypothesized that abolishing this gut
microbiota dysbiosis may decrease [CMPA] risk or [CMPA]





change in proportion of
faecal BSp & ER/CC
Baseline measures were
used as covariates for
ANCOVA
Median, AAF-Syn vs. AAF. Baseline proportions not given
At 8 weeks
- BSp: 35.4% vs. 9.7%, p < 0.001
- ER/CC: 9.5% vs. 24.2%, p < 0.001





BSp and ER/CC were
statistically significant
at 8 weeks
“The primary objective of modifying gut microbiota using an
AAF including [synbiotics] for 8 weeks in subjects with
suspected non-IgE [CMPA] was achieved.”
“ . . . The current study showed that microbial composition of
infants with suspected non-IgE [CMPA] who received the test
formula was closer to the profile of the HBR group than those








of Candy (2018) [32]
The between-group differences in microbiota composition seen at week 8
(primary trial endpoint) were maintained with longer study follow-up. At
weeks 12 and 26, the AAF-Syn group had a higher percentage of BSp and a
lower percentage of ER/CC compared with the AAF group. Mean AAF-Syn
vs. AAF:
At baseline (0 weeks)
- BSp 26.6% vs. 17.7%, p = 0.23 NS
- ER/CC 23.6% vs. 13.4%, p = 0.07 NS
At 8 weeks
- BSp 38.4% vs. 13.1%, p = 0.002
- ER/CC 6.3% vs. 25.5%, p < 0.001
At 12 weeks
- BSp 49.7% vs. 17.1%, p = 0.002
- ER/CC 7.5% vs. 32.1%, p = 0.002
At 26 weeks
- BSp 48.8% vs. 15.1%, p < 0.001
- ER/CC 13.1% vs. 33.9%, p < 0.001
Between groups
comparison for both
BSp and ER/CC were
statistically significant
at 26 weeks
“ . . . In conclusion, use of the AAF including specific
synbiotics investigated in this study resulted in a sustained
improvement in gut microbiota composition over 26 weeks
. . . ”
“ . . . it may suggest that the effects on gut microbiota by AAF
including synbiotics can even be maintained in a [CMPA]
population receiving systemic antibiotics.”
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Table 5. Cont.
Lead Author







from Candy (2018) [32]
and Fox (2019) [33].




Diversity in faecal microbiota increased over time in both groups. The effect
was less pronounced in the AAF-Syn group. Mean difference per week from
week 0 to 26
- PD: −0.022 units, p = 0.069 NS
- SI: −0.026 units, p = 0.005
Estimated average difference AAF-Syn vs. AAF was significant
At 12 weeks:
- PD: −0.349 units, p = 0.031; SI: −0.236 units, p= 0.049
At 26 weeks:




“ . . . AAF including the specific synbiotics offers an effective
nutritional strategy to modulate the gut microbiota of infants
with suspected non-IgE mediated [CMPA] closer to a healthy
breastfed profile . . . ”
“The AAF including synbiotics compared to the AAF without
synbiotics showed a more gradual increment over time of
bacterial diversity, which is also typically observed in
longitudinal studies investigating early life gut microbiota








BSp, LSp and adult-type
genera; faecal bacterial
species diversity
At 6 and 12 months, compared to AAF, AAF-Syn was associated with:
- Increased relative abundances of Bifidobacterium and Lactobacillus and
decreased relative abundances of adult-type genera (Blautia, Tyzzerella
and Romboutsia)
- Lower overall bacterial diversity
- Higher BSp diversity
Data not given.
p-values not reported
“The predominant abundance of Bifidobacterium in subjects
receiving [AAF-Syn] was reflected in lower overall diversity
at 6 and 12 months.”
“ . . . Subjects receiving [AAF-Syn] showed increased diversity
of species within the genus Bifidobacterium compared to AAF
at 6 and 12 months.”
CMPA: cow’s milk protein allergy; AAF-Syn: amino acid formula with synbiotics; AAF: amino acid formula; BSp: Bifidobacterium; CH: Clostridium histolyticum; ER/CC: Eubacterium rectale/Clostridium coccoides; GI:
Gastro-intestinal; PD: Phylogenetic diversity; SI: Shannon index; LSp: Lactobacillus; GI: gastrointestinal; HBR: healthy breastfed reference.
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3.3.5. Other Outcomes
Stool Characteristics
Three publications (2 RCT; n = 181) reported stool characteristics (colour, frequency,
consistency) in infants with IgE or non IgE mediated CMPA who received AAF-Syn or
AAF for 8 to 16 weeks [32,33,39], although quantitative data were not given in all cases
(Supplementary Table S2). One publication reported that stool colour was significantly
preferred by parents of infants who received AAF-Syn compared to parents of those who
received AAF alone, at weeks 0–2 (p = 0.014), 2–4 (p = 0.010) and 4–12 (p = 0.008) [39], while
the other two publications reported no significant differences [32,33]. One publication
reported slightly lower average stool frequency with AAF-Syn compared to AAF alone
at week 8 (1.88 ± 0.19 vs. 1.98 ± 0.15, p = 0.015) [32], while two publications found
no significant differences between groups [33,39]. No significant differences in stool
consistency were reported.
Growth
Three publications (2 RCT; n = 181) reported growth parameters (weight, length and
head circumference) for infants with IgE or non IgE mediated CMPA who received AAF-
Syn or AAF for periods ranging from 8 to 16 weeks [32,33,39] (Supplementary Table S3).
All publications reported that growth was in line with the expected ranges for age at 8
weeks [32,33] and 16 weeks [39], with no significant differences between groups.
4. Discussion
To our knowledge, this is the first systematic review to examine the effect of hy-
poallergenic formulae with synbiotics, in infants with IgE or non IgE mediated CMPA.
It demonstrates that a specially formulated AAF with synbiotics (Bifidobacterium breve
M16-V and prebiotics including chicory-derived oligo-fructose and long chain inulin;
AAF-Syn) is as effective as AAF alone in resolving allergic symptoms and promoting
normal growth, and may have additional clinical benefits for CMPA infants. Fewer infants
who took AAF-Syn had infections and hospitalisations and used medications including
antibiotics, compared to those on AAF. Whilst it is difficult to attribute causation, these
benefits could be linked to the significant changes seen in the gut microbiota with AAF-Syn,
which occurred as early as 8 weeks and were maintained up to 12 months, indicating an
improvement of gut dysbiosis which is common in formula-fed infants, and those with
CMPA [14–17].
While a healthy breastfed infant typically has a less diverse microbiome than an older
child or adult, with a higher prevalence of Bifidobacterium and Lactobacillus [46], microbes
in infants with CMPA follow an inverse pattern with a greater proportion of Eubacterium
rectale and Clostridium coccoides species. This review has shown that use of AAF-Syn led to
statistically significant increases in Bifidobacterium species, decreases in Eubacterium rectale
and Clostridium coccoides species, and reduced bacterial diversity. This colonisation pattern
appears to be closer to that seen in healthy breastfed infants, and could be associated in
some way with the beneficial impact seen on the clinical phenotype of infants managed
with this approach to treatment, with particular implications for prevention of infections.
Indeed, breastfed infants are known to be less susceptible to infections than formula
fed infants. It has been hypothesised that this is due to the early colonisation of Gram-
positive, anaerobic bacteria such as bifidobacteria, which promote the production of lactic
and acetic acids. This results in a reduction of faecal pH which thereby inhibits the growth
of some pathogens [46]. Such metabolic activity was observed in this review, with an
increase in acetic acid and an associated decrease in pH from faecal samples, although
findings were not consistent between studies, indicating a shortage of information in this
area. Pathogen colonisation may also be inhibited by other mechanisms, as bifidobacteria
compete for nutritional substrates and epithelial adhesion sites in the gut [46], which may
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go some way to explain the reductions in infections that were observed with AAF-Syn in
this review.
There is emerging evidence to suggest that infections may be more prevalent in
children with allergic conditions than their matched counterparts; in particular, the concur-
rence of allergy and ear infections has been extensively investigated [47–50], with studies
finding an allergic origin of recurrent ear infections, particularly when IgE sensitivity
is present [51,52]. Different causal mechanisms have been hypothesised, including ob-
struction and impaired functionality of the Eustachian tube secondary to allergic cytokine
regulated inflammation [53]. While further research is required to fully understand the
complex role of the gut microbiome in infective episodes, the modulating effect of gut
microbiota on systemic inflammatory and immunological responses is recognised [18,46].
For example, Bifidobacterium breve is thought to induce epithelial cell maturation which
may protect against pathogenic bacteria, and to induce anti-inflammatory processes [18].
This effect is supported by the findings of this review, in which significant changes in
faecal microbial proportions among infants who received AAF-Syn was accompanied
by reductions in rates of infection, including ear infections and significant reductions in
hospitalisation rates.
Given the above findings, it is not surprising that the use of AAF-Syn was also
associated with a reduction in the usage of medications, including antibiotics (notably
amoxicillin) and in hospitalisation, which have important economic implications. Any
nutritional intervention which reduces prescription of medications to treat infections is
economically beneficial to health services. Each year, the net ingredient cost of medica-
tions prescribed in the community to treat infections equates to over £294 million in the
UK [54–57]. Amoxicillin remains the most commonly prescribed antibiotic [58], so the
reduction in its usage with AAF-Syn is of particular interest. Furthermore, the results of
our simple cost analysis based on hospital admissions alone indicated potential savings
per infant, which may be even greater if other changes in healthcare resources, such as
specialist appointments and medications, were also taken into account.
The heterogeneity in study designs, outcomes, follow-up period and statistical as-
sumptions make comprehensive comparison of studies in this review challenging and
necessitate some caution when interpreting the results of meta-analyses. That said, the
similarity of outcome data collection methods in these studies (such as fluorescent in situ
hybridisation used to measure faecal microbiota) supports the use of meta-analysis for
the purpose of outcome exploration, and the use of random effect models for sensitivity
analysis supports our conclusions. There is also a high degree of qualitative consistency
between included studies when AAF-Syn is given to infants with CMPA, showing benefits
to rates of infections, antibiotic usage and hospitalisation for infection, which supports
the notion of true health effects. These findings are further substantiated by other clinical
trials which have demonstrated similar outcomes within different study populations, or
with other infant formulae with synbiotics. A recent study of healthy formula-fed infants
showed significant improvements in faecal microbiota profile, to be more similar to that of
a healthy breast-fed reference group, when infants were given a whole-protein infant for-
mula containing synbiotics for 6 weeks [59]. Another study of 115 healthy infants showed
that feeding with AAF-Syn for 16 weeks led to fewer infants having infective episodes
(25%) compared to AAF alone (41%) (p-value not given) [38]. Similarly, a study of infants
with atopic dermatitis showed that fewer infants used antibiotics while receiving eHF-Syn
(2.2%), compared to those who were given eHF alone (11.4%) [42]. To note, this study was
not included in the review as subjects did not have established CMPA.
In fact, relatively few RCTs of hypoallergenic formulae containing synbiotics have
been carried out in infants with CMPA, so whilst this review set out to summarise the
published data on the use of hypoallergenic formula containing synbiotics in infants with
CMPA, only a relatively small number of studies of AAF-Syn were identified and included,
and all relate to a single AAF containing a specific synbiotic, effects of which are constituent-
specific and should not be generalised to other pre- or probiotics. Whilst synbiotics have
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been combined with eHF and subjected to extensive research within cohorts of healthy
infants and infants with atopic dermatitis, demonstrating similar effects on microbiota,
allergic symptoms and growth within normal ranges [41,42,44], no RCTs of this eHF-Syn
have been conducted in infants with CMPA. This raises interesting questions about the
broader usage of hypoallergenic formulae with synbiotics, and particularly about the use
of eHF-Syn in infants with diagnosed CMPA, which invites an important area for further
research.
Three key findings of this review relate to the effect of AAF-Syn on gut microbiota,
infections and medications. The former is measured in the predefined outcomes of the
component studies, with both the latter comprised of exploratory outcomes. Whilst we
consequently cannot rule out structural bias in the observations related to infections and
medications, the high degree of between-study consistency would imply benefits of use.
Although the studies in this review include a range of disease severity, including both
IgE and non IgE mediated allergic diagnoses, in usual clinical practice AAF are typically
reserved for patients at the severe end of the allergic disease spectrum and those who do
not tolerate an eHF. Given the clinical, social and financial impacts of severe CMPA, this
is potentially the group of greatest clinical interest. Larger RCTs and real-world evidence
studies investigating the impacts of AAF-Syn on infection rates, medication usage and
hospital admissions, particularly in the longer term, would be useful to substantiate and
better quantify outcomes observed in this review. In turn, a health economic analysis
should be conducted to estimate the cost-effectiveness of AAF-Syn.
5. Conclusions
Gut dysbiosis is common in CMPA and has implications for immune and allergic
development. This systematic review shows that the addition of a synbiotic to an AAF
leads to allergic symptom resolution and normal growth, equally as well as AAF in
infants with CMPA. In addition, the findings show that the use of AAF-Syn results in
improvement of dysbiosis, and is associated with reductions in infections, medication usage
(including antibiotics) and hospital admissions, with potential associated cost savings.
There is a need to understand mechanisms of action, the extent to which AAF-Syn reduces
infections, associated healthcare usage and the economic impacts of this, and whether
similar outcomes are also achieved in infants with CMPA with eHF-Syn. Findings of this
systematic review from good quality studies of heterogenous cohorts support the use of
a specific AAF-Syn to improve outcomes, and the need for further research to optimise
treatment protocols for infants with CMPA.
Supplementary Materials: The following are available online at https://www.mdpi.com/2072-664
3/13/3/935/s1: Table S1: Individual publication results of clinical symptoms and allergenicity in
infants receiving AAF-Syn vs. AAF, Table S2: Individual publication results of stool characteristics in
infants receiving AAF-Syn vs. AAF, Table S3: Individual publication results of growth parameters in
infants receiving AAF-Syn vs. AAF.
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